Sustained Intensive Treatment and Long-term Effects on HbA
Journal
Diabetes care
ISSN: 1935-5548
Titre abrégé: Diabetes Care
Pays: United States
ID NLM: 7805975
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
16
06
2020
accepted:
01
10
2020
pubmed:
18
11
2020
medline:
19
8
2021
entrez:
17
11
2020
Statut:
ppublish
Résumé
Continuous glucose monitoring (CGM) reduces HbA The GOLD trial was a randomized crossover trial performed over 16 months of CGM treatment in people with T1D treated with MDI. People completing the trial ( The primary end point of the change in HbA The SILVER study supports beneficial long-term effects from CGM on HbA
Identifiants
pubmed: 33199470
pii: dc20-1468
doi: 10.2337/dc20-1468
doi:
Substances chimiques
Blood Glucose
0
Glycated Hemoglobin A
0
Hypoglycemic Agents
0
Insulin
0
Silver
3M4G523W1G
Banques de données
figshare
['10.2337/figshare.13042586']
ClinicalTrials.gov
['NCT02465411']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
141-149Informations de copyright
© 2020 by the American Diabetes Association.